Rachel Vatnsdal

Stock Analyst at JP Morgan

(1.2)
# 1913
Out of 5,370 analysts
67
Total ratings
44.19%
Success rate
12.82%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
TXG 10x Genomics
Maintains: Neutral
12 9
11.03 -18.4% 4 May 9, 2025
TWST Twist Bioscience
Maintains: Underweight
40 33
35.01 -5.74% 2 May 6, 2025
RGEN Repligen
Maintains: Overweight
200 190
126.08 50.7% 6 Apr 29, 2025
RVTY Revvity
Maintains: Neutral
120 100
96.31 3.83% 4 Apr 29, 2025
NVST Envista Holdings
Maintains: Neutral
20 19
19.05 -0.26% 4 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
380 390
347.88 12.11% 4 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
50 55
71.99 -23.6% 3 Feb 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
50 55
49.13 11.95% 1 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
165 160
119.07 34.37% 6 Nov 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
650 670
404.82 65.51% 8 Sep 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
88 80
70.73 13.11% 3 Aug 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
17 20
4.92 306.5% 3 Aug 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Aug 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
1300 1400
1182.83 18.36% 2 Aug 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
5 6
10.26 -41.52% 4 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Apr 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
60 90
39.02 130.65% 2 Feb 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
250 270
200.98 34.34% 4 Dec 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Nov 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
90 45
n/a n/a 1 May 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
n/a
n/a n/a 2 Nov 10, 2022